New heart device aims to zap away irregular rhythm

NCT ID NCT06510556

Recruiting now Disease control Sponsor: Boston Scientific Corporation Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 28, 2026 · Updated 4 times

Summary

This study is testing a new device called the FARAFLEX system, which uses targeted electrical pulses to treat atrial fibrillation, a common heart rhythm problem. About 250 adults with persistent or paroxysmal atrial fibrillation will take part. The goal is to see if the device is safe and can effectively restore a normal heart rhythm.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: FARAFLEX mapping and pulsed field ablation (PFA) catheter
What this could lead to: If successful, this could provide a new, safer option for treating atrial fibrillation by using targeted electrical pulses instead of heat or cold.
What could go wrong: This is an early feasibility study, so the device may not work as well as expected or could cause side effects like heart rhythm problems or blood clots. Results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ATRIAL FIBRILLATION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

atrial fibrillation paroxysmal atrial fibrillation persistent atrial fibrillation

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ATRIAL FIBRILLATION PAROXYSMAL AF PERSISTENT ATRIAL FIBRILLATION

Contacts and locations

Locations

Fondazione PTV - Policlinico Tor Vergata
RECRUITING

Roma, Italy
Klinicki bolnicki centar Split
RECRUITING

Split, Croatia
Nemocnice Na Homolce Hospital
RECRUITING

Prague, Czechia
UZ Brussel Hospital
RECRUITING

Brussels, Belgium

More trials for these conditions

Other studies related to the condition(s) this trial covers.